PMID- 16608423
OWN - NLM
STAT- MEDLINE
DCOM- 20060803
LR  - 20060412
IS  - 1744-8395 (Electronic)
IS  - 1476-0584 (Linking)
VI  - 5
IP  - 2
DP  - 2006 Apr
TI  - Sensitization of malignant glioma to chemotherapy through dendritic cell 
      vaccination.
PG  - 233-47
AB  - Drug resistance represents a major cause of chemotherapy failure in patients with 
      cancer. The characterization of the molecular pathways involved in drug 
      resistance has provided new targets to circumvent or reverse chemotherapy 
      resistance. Many of these target proteins are often overexpressed in human glioma 
      and have been identified as tumor antigens, which implicate the development of 
      immunotherapy as a therapeutic strategy. Dendritic cells (DCs) are the most 
      potent antigen-presenting cells of the immune system and have been demonstrated 
      to stimulate antibody and cell-mediated immune responses against tumor-associated 
      antigens. Ex vivo-generated and tumor antigen-loaded DCs have been successfully 
      introduced to clinical vaccination protocols, which have proven to be feasible 
      and effective in some glioma patients. Most importantly, immunotherapy followed 
      by chemotherapy could significantly increase 2-year survival in malignant glioma 
      patients, which obviously demonstrates that DC vaccination could increase the 
      sensitivity of tumor cells to chemotherapy. This review focuses on recent 
      advances in the identification of tumor-associated antigen in glioma, as well as 
      novel insights into their biological function related to drug resistance. These 
      insights may provide the rationale for a novel strategy of a DC cancer vaccine 
      that sensitizes tumor cells to chemotherapy. In addition, the current research 
      status and the future direction of a DC-based vaccine to treat glioma in animal 
      models and clinical trials will also be discussed.
FAU - Liu, Gentao
AU  - Liu G
AD  - Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, and Division 
      of Hematology/Oncology, Cedars-Sinai Medical Center/David Geffen Schol of 
      Medicine at UCLA, 8700 Beverly Blvd, Los Angeles, CA 90048, USA. Liug@cshs.org
FAU - Black, Keith L
AU  - Black KL
FAU - Yu, John S
AU  - Yu JS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Vaccines
JT  - Expert review of vaccines
JID - 101155475
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Antineoplastic Agents/*immunology/*therapeutic use
MH  - Cancer Vaccines/*immunology/therapeutic use
MH  - Dendritic Cells/immunology/*transplantation
MH  - Dose-Response Relationship, Immunologic
MH  - Glioma/*immunology/*therapy
MH  - Humans
RF  - 126
EDAT- 2006/04/13 09:00
MHDA- 2006/08/04 09:00
CRDT- 2006/04/13 09:00
PHST- 2006/04/13 09:00 [pubmed]
PHST- 2006/08/04 09:00 [medline]
PHST- 2006/04/13 09:00 [entrez]
AID - 10.1586/14760584.5.2.233 [doi]
PST - ppublish
SO  - Expert Rev Vaccines. 2006 Apr;5(2):233-47. doi: 10.1586/14760584.5.2.233.